Old Pathogens–New Patient Types: Infections in a CAR T‐Cell Recipient. Could It Get Any More Complicated?

ABSTRACT The case discussed involves a 41‐year‐old Italian man who was a candidate for chimeric antigen receptor T‐cell therapy (CAR‐T) for mediastinal diffuse large B‐cell lymphoma. His CAR‐T treatment was postponed several times due to prolonged relapsing COVID‐19 and new onset of pulmonary Mycobacterium tuberculosis diseases. After 11 weeks of antimycobacterial treatment, CAR T‐cell therapy was performed, but complicated by cytokine release syndrome (CRS) and immune effector cell‐associated neurotoxicity syndrome (ICANS). Two months after CAR‐T, the patient developed invasive pulmonary aspergillosis due to A. fumigatus . He was successfully treated with a 6‐month course of antitubercular therapy and an 8‐month course of antifungal therapy with isavuconazole. Lobectomy was performed due to episodes of severe hemoptysis. The challenging issues of diagnosis, choice, and management of treatments, including drug–drug interactions and length of therapy, are discussed. image